Other Events ·
Shareholders approve reverse split authority and reject supermajority vote elimination
MBRXMoleculin Biotech, Inc.
Moleculin Biotech stockholders approved an amendment to the Certificate of Incorporation granting the Board authority to effect a reverse stock split at a ratio between 1-for-2 and 1-for-20, determined by the Board prior to the one-year anniversary. Conversely, shareholders rejected an amendment to eliminate supermajority voting requirements for future Charter amendments. The meeting also saw approval of the 2024 Equity Plan share increase and director elections. Moleculin Biotech is a clinical-stage biopharmaceutical company focused on developing therapies for cancer.